Advanced search
Publication Cover
Biotechnology & Biotechnological Equipment Volume 33, 2019 - Issue 1
Submit an article Journal homepage
1,471
Views
2
CrossRef citations to date
0
Altmetric
Articles

High mobility group box 1 protein (HMGB1) stimulates the nuclear accumulation of p53

Maria SchröderDepartment of Structure and Function of Chromatin, Institute of Molecular Biology “Roumen Tsanev’’, Bulgarian Academy of Sciences, Sofia, BulgariaView further author information
,
Shazie Yusein-MyashkovaDepartment of Structure and Function of Chromatin, Institute of Molecular Biology “Roumen Tsanev’’, Bulgarian Academy of Sciences, Sofia, BulgariaView further author information
,
Jordana TodorovaDepartment of Structure and Function of Chromatin, Institute of Molecular Biology “Roumen Tsanev’’, Bulgarian Academy of Sciences, Sofia, BulgariaView further author information
,
Evdokia PashevaDepartment of Structure and Function of Chromatin, Institute of Molecular Biology “Roumen Tsanev’’, Bulgarian Academy of Sciences, Sofia, BulgariaView further author information
&
Iva UgrinovaDepartment of Structure and Function of Chromatin, Institute of Molecular Biology “Roumen Tsanev’’, Bulgarian Academy of Sciences, Sofia, BulgariaCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-0116-0079View further author information
ORCID Icon
Pages 645-650 | Received 12 Dec 2018, Accepted 02 Apr 2019, Published online: 22 Apr 2019

References

  • Livesey KM, Kang R, Vernon P, et al. p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res. 2012;72:1996–2005.
  • Livesey KM, Kang R, Zeh HJ, 3rd, et al. Direct molecular interactions between HMGB1 and TP53 in colorectal cancer. Autophagy. 2012;8:846–848.
  • Liang SH, Clarke MF. Regulation of p53 localization. Eur J Biochem. 2001;268:2779–2783.
  • Inoue K, Fry EA, Frazier DP. Transcription factors that interact with p53 and Mdm2. Int J Cancer. 2016;138:1577–1585.
  • Zheng HC. The molecular mechanisms of chemoresistance in cancers. Oncotarget. 2017;8:59950–59964.
  • Matsuura K, Canfield K, Feng W, et al. Metabolic regulation of apoptosis in cancer. Int Rev Cell Mol Biol. 2016;327:43–87.
  • Ugrinova I, Pasheva E. HMGB1 protein: a therapeutic target inside and outside the cell. Adv Protein Chem Struct Biol. 2017;107:37–76.
  • Ugrinova I, Zlateva S, Pashev IG, et al. Native HMGB1 protein inhibits repair of cisplatin-damaged nucleosomes in vitro. Int J Biochem Cell Biol. 2009;41:1556–1562.
  • Topalova D, Ugrinova I, Pashev IG, et al. HMGB1 protein inhibits DNA replication in vitro: a role of the acetylation and the acidic tail. Int J Biochem Cell Biol. 2008;40:1536–1542.
  • Stros M, Muselikova-Polanska E, Pospisilova S, et al. High-affinity binding of tumor-suppressor protein p53 and HMGB1 to hemicatenated DNA loops. Biochemistry. 2004;43:7215–7225.
  • McKinney K, Prives C. Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol Cell Biol. 2002;22:6797–6808.
  • Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418:191–195.
  • Kostova N, Zlateva S, Ugrinova I, et al. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem. 2010;337:251–258.
  • Mitkova E, Ugrinova I, Pashev IG, et al. The inhibitory effect of HMGB-1 protein on the repair of cisplatin-damaged DNA is accomplished through the acidic domain. Biochemistry. 2005;44:5893–5898.
  • Pasheva EA, Pashev IG, Favre A. Preferential binding of high mobility group 1 protein to UV-damaged DNA. Role of the COOH-terminal domain. J Biol Chem. 1998;273:24730–24736.
  • Elenkov I, Pelovsky P, Ugrinova I, et al. The DNA binding and bending activities of truncated tail-less HMGB1 protein are differentially affected by Lys-2 and Lys-81 residues and their acetylation. Int J Biol Sci. 2011;7:691–699.
  • Osmanov T, Ugrinova I, Pasheva E. The chaperone like function of the nonhistone protein HMGB1. Biochem Biophys Res Commun. 2013;432:231–235.
  • Choong ML, Yang H, Lee MA, et al. Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Cell Cycle. 2009;8:2810–2818.
  • Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137:413–431.
  • Yan HX, Wu HP, Zhang HL, et al. p53 promotes inflammation-associated hepatocarcinogenesis by inducing HMGB1 release. J Hepatol. 2013;59:762–768.
  • Banerjee S, Kundu TK. The acidic C-terminal domain and A-box of HMGB-1 regulates p53-mediated transcription. Nucleic Acids Res. 2003;31:3236–3247.
  • Logsdon CD, Fuentes MK, Huang EH, et al. RAGE and RAGE ligands in cancer. Curr Mol Med. 2007;7:777–789.
  • Tesarova P, Kalousova M, Zima T, et al. HMGB1, S100 proteins and other RAGE ligands in cancer - markers, mediators and putative therapeutic targets. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;160:1–10.
  • Imamura T, Izumi H, Nagatani G, et al. Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein. J Biol Chem. 2001;276:7534–7540.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.